Glenmark Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Glenmark Pharmaceuticals Ltd reported a 14.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.5%.
• Its expenses for the quarter were up by 0.5% QoQ and 2.1% YoY.
• The net profit decreased 103.9% QoQ and decreased 86.2% YoY.
• The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 1.66 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glenmark Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its focus on innovation and the development of generic drugs. The company operates globally, providing a wide array of pharmaceutical formulations and active pharmaceutical ingredients. Glenmark is heavily invested in research and development, with a pipeline that includes treatments for respiratory, dermatology, and oncology conditions. Recent developments in the company have focused on expanding their product offerings and enhancing their presence in emerging markets. However, specific recent developments are not available within the provided data, and thus, it is crucial to refer to the latest company announcements and reports for a comprehensive understanding.

Revenue

In Q1FY26, Glenmark Pharmaceuticals reported a total income of ₹3290.88 crores. This figure marks a slight year-over-year increase of 0.5% from the ₹3275.68 crores recorded in Q1FY25. However, there was a quarter-over-quarter decline of 14.2% compared to the ₹3836.12 crores reported in Q4FY25. This fluctuation in revenue might reflect changes in market demand, product sales, or other operational factors not specified in the data. Quarter-over-quarter changes often reflect seasonal variations, whereas year-over-year comparisons provide insight into the company's longer-term growth trajectory.

Profitability

Glenmark's profitability metrics for Q1FY26 indicate significant challenges. The profit before tax stood at ₹95.58 crores, which is a substantial decline both year-over-year, by 79.3%, and quarter-over-quarter, by 82.0%. The profit after tax was ₹46.97 crores, a steep drop from ₹340.24 crores in Q1FY25 and a recovery from a negative figure of ₹-1214.27 crores in Q4FY25. Taxes in Q1FY26 amounted to ₹48.60 crores, compared to ₹122.10 crores in Q1FY25 and a notably high ₹1769.47 crores in the previous quarter. Earnings per share (EPS) also reflect this trend, registering at ₹1.66 compared to ₹12.06 in the previous year and a negative ₹-43.18 in the last quarter. These metrics highlight significant fluctuations in profitability, influenced by various operational and external factors.

Operating Metrics

The operating expenses of Glenmark Pharmaceuticals in Q1FY26 were recorded at ₹2872.08 crores, showing a slight increase of 2.1% from the previous year’s figure of ₹2813.34 crores, and a marginal quarter-over-quarter increase of 0.5% from ₹2858.51 crores in Q4FY25. This steady rise in expenses could be attributed to various operational needs or strategic investments. The expense trends, when compared with revenue and profitability figures, offer insights into the company's operational efficiency and cost management strategies. These metrics are crucial for understanding how the company balances its revenue generation with its cost structures to sustain profitability.